India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
After years of sharp increases and shrinking coverage options, Florida’s home insurance market is showing its strongest signs of recovery yet. Multiple insurers are proposing significant premium cuts for 2026 — some in the double digits — as storm‑loss data improves and private carriers re‑enter the state. Citizens Insurance is also seeking its first broad rate reduction in a decade, potentially lowering costs for millions of homeowners. This shift could boost affordability and confidence across Florida’s real estate and mortgage markets heading into the new year.
An AI company that began in a bedroom is now shaking the foundations of the lending industry. Salient, led by CEO Ari Malik, has skyrocketed to a $500 million valuation by fixing one of finance’s messiest problems: debt servicing. With zero customer churn, 100% pilot-to-contract conversions, and AI agents reportedly 30 times more compliant than humans, Salient is redefining how lenders manage loans. Its rapid rise highlights a new era where trust, regulation‑ready AI, and deep industry understanding are becoming essential for professionals across real estate, mortgage, finance, and insurance.
Redmond, Washington is tackling its housing crisis with Prisma, a six‑story, transit‑oriented development built on discounted surplus land from Sound Transit. The project will deliver 328 deeply affordable units—most reserved for households earning 50 percent of AMI or less, including families and people with disabilities. Enabled by a rare cross‑sector funding partnership, Prisma showcases how cities can combine transit investment, public resources, and private support to create long‑term, equitable housing solutions.
Citizens Property Insurance Corp. is recommending rate decreases for millions of Florida homeowners in 2026, marking the first potential premium drop in over a decade. If approved by state regulators, personal-line policies would fall an average of 2.6%, with some homeowners seeing reductions up to 11.5%. The shift reflects growing market stability driven by recent insurance reforms and increased private‑sector participation, though not all counties will benefit equally.
Despite alarming headlines, experts say AI isn’t the true driver behind Wall Street job cuts. Major banks like JPMorgan and Goldman Sachs are trimming staff, but economists point to post‑pandemic overhiring and economic uncertainty—not robots—as the real cause. While banks are investing heavily in AI tools, actual AI‑driven layoffs remain minimal. Instead, AI is slowing new hiring, reshaping roles, and pushing professionals across finance, real estate, and other industries to upskill rather than fear replacement.
Artificial intelligence is reshaping the real estate industry in 2025, powering a new surge of growth and maturity in the proptech sector. AI tools once considered experimental—such as predictive analytics, automated valuations, and digital transaction platforms—are now becoming essential to real estate, mortgage, insurance, and finance workflows. With rising investor confidence and widespread professional adoption, AI‑driven proptech is transforming how the industry operates and what skills modern professionals need to stay competitive.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
